Yan Wei, Wang Ting-Yu, Fan Qi-Ming, Du Lin, Xu Jia-Ke, Zhai Zan-Jing, Li Hao-Wei, Tang Ting-Ting
Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Wendeng Zhenggu Hospital of Shandong Province, Wendeng, 264400, China.
Acta Pharmacol Sin. 2020 Apr;41(4):581-582. doi: 10.1038/s41401-019-0252-6.
During re-read of our previously article Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of micepublished in Acta Pharmacologica Sinica, we were regretted to point out a mistake shown in Fig. 2a. The representative figure chosen to indicate the inhibitory effect of 4 mg/kg of plumbagin treatment at 1 week against MDA-MB-231SArfp cells localization within bone environment was incorrect due to the mishandling in manuscript preparation. Although this correction does not affect the results and conclusion of the paper, all the authors agree on the correction of our negligence as providing the corrected Fig. 2a presented below. We feel sorry and apologize for all the inconvenience it caused.An amendment to this paper has been published and can be accessed via a link at the top of the paper.
在重新阅读我们之前发表于《中国药理学报》的文章“白花丹素抑制小鼠骨微环境中癌细胞生长和破骨细胞形成”时,我们遗憾地指出图2a中存在一个错误。由于稿件准备过程中的失误,所选用于表明4mg/kg白花丹素处理1周对MDA-MB-231SArfp细胞在骨环境中定位的抑制作用的代表性图片有误。尽管这一更正不影响论文的结果和结论,但所有作者一致同意对我们的疏忽进行更正,如下所示为更正后的图2a。对于由此造成的所有不便,我们深感抱歉并致以歉意。本文的勘误已发表,可通过文章顶部的链接访问。